The Glycaemic Effects of Glucerna® in Critically Ill Patients.

Glucerna in Critically Ill Patients (GluCip Trial): Investigating the Glycaemic Effects of a Reduced-carbohydrate, Modified-fat, Fiber-containing Enteral Formula (Glucerna®) in Critically Ill Patients.

To investigate whether the administration of Glucerna achieves less glycaemic variability, defined as the mean absolute glucose (MAG) change, and better glycaemic control compared to a standard high-carbohydrate enteral formula. Continuous glucose monitoring technology will be used to evaluate glycaemic variability and glycaemic control.

Inclusion Criteria:

• Age ≥ 18 years;
• Patients with an anticipated stay of at least 48 hours of admission to the intensive care
• Expected to receive enteral feeding for at least 48 hrs
• Indication for glucose regulation with insulin (according to the current glucose treatment protocol)
• Patient or surrogate understands and signs informed consent document.

Exclusion Criteria:

• Patients with pre-existing contraindications to enteral feeding or to placement of a continuous glucose monitoring system
• Patients previously randomised into the GluCip trial
• Any disease or condition which the investigator or treating physician feels would interfere with the trial or the safety of the patient.